Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Growth Metrics
Income Statement
Others
Ratios

Cresco Labs (CRLBF) Total Liabilities (2019 - 2025)

Cresco Labs (CRLBF) has disclosed Total Liabilities for 5 consecutive years, with $967.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Total Liabilities changed N/A year-over-year to $967.2 million, compared with a TTM value of $967.2 million through Dec 2024, changed N/A, and an annual FY2024 reading of $967.2 million, changed N/A over the prior year.
  • Total Liabilities was $967.2 million for Q4 2024 at Cresco Labs, down from $996.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $996.0 million in Q4 2022 and bottomed at -$755.6 million in Q4 2021.
  • Average Total Liabilities over 4 years is $466.2 million, with a median of $812.2 million recorded in 2020.
  • The sharpest move saw Total Liabilities tumbled 214.95% in 2021, then soared 231.82% in 2022.
  • Year by year, Total Liabilities stood at $657.3 million in 2020, then crashed by 214.95% to -$755.6 million in 2021, then skyrocketed by 231.82% to $996.0 million in 2022, then fell by 2.89% to $967.2 million in 2024.
  • Business Quant data shows Total Liabilities for CRLBF at $967.2 million in Q4 2024, $996.0 million in Q4 2022, and -$755.6 million in Q4 2021.